U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06814496) titled 'Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors' on Jan. 29.
Brief Summary: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle ...